US FDA News: FDA expands approval of Sutent to reduce the risk of kidney cancer returning

FDA approves first adjuvant treatment for adult patients who are at a high risk of kidney cancer returning after a kidney has been removed.
Read more: FDA expands approval of Sutent to reduce the risk of kidney cancer returning